Corcept Therapeutics
Clinical trials sponsored by Corcept Therapeutics, explained in plain language.
A commercial-stage pharmaceutical company developing drugs for severe metabolic and psychiatric disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise against fatty liver disease in Mid-Stage trial Results expected Sep 2026 (estimated)
- New drug duo aims to fight Hard-to-Treat cancers Results expected Sep 2026 (estimated)
- New hope for ALS: experimental drug aims to slow muscle decline Results expected Oct 2026 (estimated)
- New drug miricorilant tested for fatty liver disease safety Results expected Oct 2026 (estimated)
- New drug shows promise for Long-Term control of cushing syndrome Results expected Dec 2026 (estimated) May already have reported ↗
-
New drug combo shows promise for resistant ovarian cancer
Disease control CompletedThis study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the c…
Phase 2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug aims to tame cortisol overload from adrenal tumors
Disease control CompletedThis Phase 3 trial tested a drug called relacorilant in 137 people with hypercortisolism caused by adrenal adenomas or hyperplasia. The goal was to see if it could improve blood sugar control and lower high blood pressure. Participants received either relacorilant or a placebo fo…
Phase 3 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 14:09 UTC
-
Healthy volunteers help pick best pill form for new drug
Knowledge-focused CompletedThis study enrolled 18 healthy adults to compare how the body absorbs miricorilant from different tablet types. Participants received the drug in various forms and doses on separate days. The goal is to find which formulation works best for future trials. This is an early-stage s…
Phase 1 • Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Hidden hormone link in stubborn high blood pressure revealed
Knowledge-focused CompletedThis study looked at over 1,100 adults in the US whose high blood pressure stays high despite taking multiple medications. Researchers checked if these people also have a hormone condition called endogenous hypercortisolism, where the body makes too much cortisol. Participants ga…
Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC